This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Earnshaw SR, Graham J, Oleen-Burkey MK, Castelli-Haley J, Johnson K.Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Applied Health Economics and Health Policy 7: 91-108, No. 2, 1 Jun 2009
Rights and permissions
About this article
Cite this article
Glatiramer acetate dominant but still expensive in RRMS. Pharmacoecon. Outcomes News 588, 7 (2009). https://doi.org/10.2165/00151234-200905880-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905880-00013